NDA 216442. Not in Drugs@FDA, which lists approved applications only; FDA's complete response letters name it.
As of Nov 22, 2026, NDA 216442 (Reproxalap) is not in Drugs@FDA, which lists approved applications; FDA has published 2 complete response letters for it.
| Mar 16, 2026 | Reproxalap | Unapproved |
| Apr 2, 2025 | Reproxalap | Unapproved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters